NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free RCKT Stock Alerts $22.34 -1.29 (-5.46%) (As of 03:21 PM ET) Add Compare Share Share Today's Range$22.06▼$23.1350-Day Range$22.80▼$30.7452-Week Range$14.89▼$32.53Volume601,702 shsAverage Volume714,119 shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$52.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rocket Pharmaceuticals alerts: Email Address Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside133.3% Upside$52.13 Price TargetShort InterestBearish12.15% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.52Based on 12 Articles This WeekInsider TradingSelling Shares$11.48 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.94) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.53 out of 5 starsMedical Sector103rd out of 907 stocksPharmaceutical Preparations Industry37th out of 422 stocks 4.4 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.15% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 4.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 2.5 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 3 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,476,424.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesApril 25, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 833 SharesApril 18, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director David P. Southwell Sells 10,000 SharesApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 12, 2024 | insidertrades.comMark Andrew White Sells 12,532 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockMarch 26, 2024 | insidertrades.comJohn Militello Sells 2,490 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockMarch 26, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director Sells $7,789,820.00 in StockApril 23, 2024 | msn.comU.S. Space & Rocket Center launches eclipse glasses donation drive for South American childrenApril 23, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 22, 2024 | msn.comNorth Korean Leader Kim Leads Rocket Drills That Simulate a Nuclear Counterattack Against EnemiesApril 19, 2024 | msn.comRocket Run raises money for Gardendale Elementary SchoolApril 19, 2024 | msn.comRonnie O’Sullivan rivals question the Rocket’s World Championship favourite tagApril 19, 2024 | americanbankingnews.comDavid P. Southwell Sells 10,000 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockApril 19, 2024 | americanbankingnews.comDavid P. Southwell Sells 70,000 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockApril 18, 2024 | investing.comRocket Pharmaceuticals executive sells over $1.9m in stockApril 17, 2024 | msn.comInjured South Carolina tailback Rocket Sanders has a timetable in mind for returnApril 17, 2024 | msn.comBrevard political consultant, Space Coast Rocket owner, arrested for alleged PPP loan fraudApril 13, 2024 | techcrunch.comSpace Force tees up new ‘responsive space’ mission from Rocket Lab and True AnomalyApril 12, 2024 | msn.comBeloved Durant Rocket Park slide staying after allApril 12, 2024 | msn.comRocket League Sideswipe Codes For April 2024April 11, 2024 | yahoo.comSpace Force tees up new 'responsive space' mission from Rocket Lab and True AnomalyApril 11, 2024 | msn.comDurant Rocket Park, Multi-Sports Complex to begin renovationsApril 10, 2024 | usnews.comRussia Aborts Angara-A5 Space Rocket Launch for Second TimeApril 5, 2024 | msn.comSyracuse Crunch rally past Laval Rocket, 3-1April 5, 2024 | seekingalpha.comRocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)April 4, 2024 | wnewsj.comRocket offense explodes late in 21-11 win over AstrosApril 2, 2024 | msn.comCan the Rocket Hold Their Position? | Laval Week In ReviewSee More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees268Year Founded2018Price Target and Rating Average Stock Price Target$52.13 High Stock Price Target$65.00 Low Stock Price Target$39.00 Potential Upside/Downside+120.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.83% Return on Assets-45.87% Debt Debt-to-Equity Ratio0.04 Current Ratio7.80 Quick Ratio7.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book4.33Miscellaneous Outstanding Shares90,504,000Free Float62,357,000Market Cap$2.14 billion OptionableOptionable Beta1.07 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Gaurav D. Shah M.D. (Age 49)CEO & Director Comp: $1.05MMr. Mayo Pujols (Age 55)Chief Technical Officer & Executive VP Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 50)Senior VP & Chief Business Officer Comp: $619.13kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Senior VP & Chief Human Resources OfficerDr. Gayatri R. Rao J.D.M.D., Chief Development Officer of LVV & Senior VPMr. Carlos MartinChief Commercial OfficerMore ExecutivesKey CompetitorsVera TherapeuticsNASDAQ:VERADyne TherapeuticsNASDAQ:DYNTG TherapeuticsNASDAQ:TGTXAvidity BiosciencesNASDAQ:RNAAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 7,900 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Sold 621,899 shares on 4/24/2024Ownership: 0.089%John MilitelloSold 833 sharesTotal: $19,050.71 ($22.87/share)EFG Asset Management Americas Corp.Sold 4,472 shares on 4/22/2024Ownership: 0.008%Hennion & Walsh Asset Management Inc.Bought 37,937 shares on 4/17/2024Ownership: 0.256%View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price target for 2024? 9 Wall Street analysts have issued 1 year price targets for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $39.00 to $65.00. On average, they expect the company's stock price to reach $52.13 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2024? Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of 2024. Since then, RCKT shares have decreased by 25.5% and is now trading at $22.34. View the best growth stocks for 2024 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings data on Monday, February, 26th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.14. During the same quarter last year, the firm earned ($0.92) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS), Harbor Health Care ETF (MEDI), Franklin Genomic Advancements ETF (HELX), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).SPDR S&P Biotech ETF (XBI) and What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.26%), Assenagon Asset Management S.A. (0.09%), Harbour Capital Advisors LLC (0.02%), Simplex Trading LLC (0.00%) and EFG Asset Management Americas Corp. (0.01%). Insiders that own company stock include David P Southwell, Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Mark Andrew White, Martin Wilson and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RCKT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
